Carillon Tower Advisers’s Acceleron Pharma XLRN Stock Holding History

Carillon Tower Advisers’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$73.6M	Buy	575,271 +350,125	+156%	+$41.1M	0.45%	65
2020 Q3	$25.3M	Sell	225,146 -444,321	-66%	-$44.2M	0.34%	96
2020 Q2	$63.8M	Buy	669,467 +233,843	+54%	+$22.5M	0.49%	66
2020 Q1	$36.6M	Sell	435,624 -222,016	-34%	-$17.3M	0.36%	95
2019 Q4	$34.9M	Hold	657,640	–	–	0.23%	152
2019 Q3	$26M	Hold	657,640	–	–	0.18%	202
2019 Q2	$27M	Hold	657,640	–	–	0.19%	203
2019 Q1	$30.6M	Hold	657,640	–	–	0.22%	172
2018 Q4	$28.6M	Hold	657,640	–	–	0.24%	164
2018 Q3	$37.6M	Hold	657,640	–	–	0.27%	148
2018 Q2	$31.9M	Sell	657,640 -285,204	-30%	-$10.4M	0.25%	145
2018 Q1	$36.9M	Hold	942,844	–	–	0.29%	113
2017 Q4	$40M	Buy	+942,844	New	+$35.4M	0.43%	80

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Carillon Tower Advisers's XLRN Position: Q4 2020 in Review

Carillon Tower Advisers increased its Acceleron Pharma (XLRN) stake by 156% in Q4 2020, buying an estimated $41.1M and bringing the position to 575,271 shares worth $73.6M. The position accounts for 0.45% of the portfolio, ranked #65.

Carillon Tower Advisers first reported a position in XLRN in Q4 2017 and has held it in 13 quarters since. 253 funds tracked by Wall St. Rank hold XLRN as of Q4 2020.

Carillon Tower Advisers held 575,271 shares of Acceleron Pharma worth $73.6M as of Q4 2020.
Carillon Tower Advisers bought 350,125 Acceleron Pharma shares in Q4 2020, an estimated $41.1M.
Acceleron Pharma made up 0.45% of Carillon Tower Advisers's portfolio in Q4 2020, its #65 holding.
Carillon Tower Advisers first reported a position in Acceleron Pharma in Q4 2017 and has held it in 13 quarters since.
253 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.